Table S1 Basal clinicopathologic characteristics of HCC patients in training and validation sets

Characteristics	Training set (n=159), n (%)	Validation set (n=103), n (%)	P value
YAP-high	103 (64.78)	27 (26.21)	<0.001
Male	143 (89.94)	91 (88.35)	0.69
Age >50 years	94 (59.12)	65 (63.11)	0.52
TBIL >17.1 µmol/L	21 (13.21)	15 (14.56)	0.76
ALT >44 U/L	75 (47.17)	36 (34.95)	0.051
AST >40 U/L	101 (63.52)	48 (46.60)	0.007
HBsAg positive	139 (87.42)	90 (87.38)	>0.99
HBeAg positive	27 (15.09)	86 (83.50)	0.92
HBV-DNA ≥2,000 IU/mL	89 (55.97)	61 (59.22)	0.60
Child-Pugh B stage	17 (10.69)	7 (6.80)	0.29
AFP >400 ng/mL	111 (69.81)	68 (66.02)	0.52
Non-anatomical hepatectomy	22 (13.84)	15 (14.56)	0.87
Surgical margin <1 cm	9 (5.66)	9 (8.74)	0.34
Bilateral tumor distribution	13 (8.18)	11 (10.68)	0.49
Tumor diameter >5 cm	87 (54.72)	54 (52.43)	0.72
Tumor number >1	41 (25.79)	26 (25.24)	0.92
Satellite nodules	125 (78.62)	75 (72.82)	0.28
Microvascular invasion	85 (53.46)	38 (36.89)	0.009
Edmondson-Steiner grade III–IV	132 (83.02)	74 (71.84)	0.03
Cirrhosis	117 (73.58)	73 (70.87)	0.63
BCLC stage: A–B	70 (44.03)	55 (53.40)	0.14

HCC, hepatocellular carcinoma; YAP, Yes-associated protein; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, glutamate aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.